TransCode Therapeutics shares Phase 1a safety and activity results for TTX‑MC138
TransCode Therapeutics presented data from its Phase 1a study of the RNA‑based candidate TTX‑MC138 at the ESMO Congress 2026 in Madrid. The multicenter, open‑label trial evaluated four dose levels between 0.8 mg/kg and 4.8 mg/kg and met its primary safety endpoint with no dose‑limiting toxicities. Dose‑dependent plasma exposure was observed, and investigators reported disease stabilization and longer progression‑free intervals in a subset of patients. The company is now moving the therapy into a Phase 2a trial under the PRE‑I‑SPY program.
Why it matters
The company says the safety and early efficacy signals support continuation of development and may influence investor sentiment, while the stock was trading at $1.74, down 1.73% after the release.
Key facts
- 1The study tested four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. investing.com
- 2No dose‑limiting toxicities were observed, meeting the primary safety endpoint. investing.com
- 3Plasma exposure increased with higher doses. investing.com
- 4Investigators noted disease stabilization and extended progression‑free intervals in some patients. investing.com
- 5RNAZ shares were priced at $1.74, down 1.73% after the announcement. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.